|
||
J. Exp. Med.,
Volume 187, Number 11, June 1, 1998 1753-1765
By


From the * Immunology Program, H. Lee Moffitt Cancer Center, University of South Florida College
of Medicine, Department of Biochemistry and Molecular Biology, Tampa, Florida 33612; the The signal pathways that control effector function in human natural killer (NK) cells are little
known. In this study, we have identified the critical role of the mitogen-activated protein kinase (MAPK) pathway in NK lysis of tumor cells, and this pathway may involve the mobilization of granule components in NK cells upon interaction with sensitive tumor target cells. Evidence was provided by biological, biochemical, and gene transfection methods. NK cell
binding to tumor cells for 5 min was sufficient to maximally activate MAPK/extracellular signal-regulatory kinase 2 (ERK2), demonstrated by its tyrosine phosphorylation and by its ability to function as an efficient kinase for myelin basic protein. MAPK activation was achieved in
NK cells only after contact with NK-sensitive but not NK-resistant target cells. In immunocytochemical studies, cytoplasmic perforin and granzyme B were both maximally redirected towards the tumor contact zone within 5 min of NK cell contact with tumor cells. A specific
MAPK pathway inhibitor, PD098059, could block not only MAPK activation but also redistribution of perforin/granzyme B in NK cells, which occur upon target ligation. PD098059 also
interfered with NK lysis of tumor cells in a 5-h 51Cr-release assay, but had no ability to block
NK cell proliferation. Transient transfection studies with wild-type and dominant-negative MAPK/ERK2 genes confirmed the importance of MAPK in NK cell lysis. These results document a pivotal role of MAPK in NK effector function, possibly by its control of movement of
lytic granules, and clearly define MAPK involvement in a functional pathway unlinked to cell growth or differentiation.
Cellular Cytotoxicity Laboratory, Austin Research Institute, Heidelberg, Victoria 3084, Australia; the § Department of Immunology, Cleveland Clinic Research Foundation, Cleveland, Ohio 44195; and
the
Department of Microbiology, University of Virginia, Charlottesville, Virginia 22908
This article has been cited by other articles:
| TABLE OF CONTENTS |
|